Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TAS-102 + bevacizumab by RAS status in refractory advanced colorectal cancer
jRCTs031180104Phase 2Completed
- Sponsor
- Taiho Pharmaceutical Co., Ltd.
- Start
- Jan 2018
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of trifluridine + tipiracil and bevacizumab in colorectal cancer (CRC) (2 cohorts), sponsored by Taiho Pharmaceutical Co., Ltd. Primary endpoint: Disease control rate by RAS mutation status. Started Jan 2018; status: completed.
02
Drugs
trifluridine + tipiracilbevacizumab
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on jRCTs031180104.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs031180104.